Novavax Inc (NVAX) Stock Price, Quote & News

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 268 2000

Website: www.novavax.com

Address:

21 Firstfield Road, Gaithersburg, United States

Trissy Sep. 14 at 2:40 AM

$NVAX Margaret (Margie) McGlynn serves as the Chair of the Board of Directors for Novavax. Filings note that she previously spent 26 years at Merck, serving as the President of Merck Vaccines and Infectious Disease

0 · Reply

TopShelfStock Sep. 14 at 2:13 AM

$NVAX The anchor is dropped, and the floor is set. ⚓✨This graphic says it all about $NVAX. The Matrix-M Platform isn't just a biotech asset; it is the ultimate anchor holding down immense underlying value and securing our future growth.Backed by gold-standard partnerships with Sanofi and Pfizer, Novavax's platform technology is built on a rock-solid foundation. Let the market fluctuate all it wants—the long-term value and growth bars are firmly locked in.Tomorrow is a new day to see this anchor hold strong. Drop a Like if you are bullish on Novavax tonight! 🪙📈🔥#Novavax #NVAX #Biotech #StocksToWatch #Bullish #ValueInvesting

0 · Reply

ddirk Sep. 14 at 1:38 AM

$NVAX Novavax and Sanofi officially became partners on May 10, 2024, when they announced their co-exclusive licensing agreement. So for 2 years we JJ has been regurgitating this partnership. Novavax and Pfizer became partners in January 2026, specifically through a Matrix-M licensing agreement. So more then 6 ms here too Ask yourself, what takes him soo long to do ANYTHING

1 · Reply

TopShelfStock Sep. 14 at 1:27 AM

$NVAX $NVAX The transformation from vaccine maker to Licensing Powerhouse is being completely mispriced by Wall Street. Between the massive Sanofi/Pfizer partnerships, the upcoming multi-billion dollar COVID-Flu combo shot, and under-the-radar cancer vaccine exploration... this is a ticking growth bomb. Short interest is playing with fire. Tomorrow is a fresh canvas. Drop a 👍 if you’re accumulating down here! 🌋🚀💎

0 · Reply

novavaxfan Sep. 13 at 10:37 PM

$NVAX https://www.verifiedmarketresearch.com/blog/top-oncology-pharma-companies/ Merck Bottom Line: Merck’s performance remains tethered to Keytruda—the world’s best-selling oncology drug—but diversification is the 2026 priority. VMR Analyst Insight: Keytruda accounts for a staggering portion of Merck’s oncology revenue. VMR predicts a strategic pivot toward ADC collaborations (e.g., with Daiichi Sankyo) to mitigate the 2028 patent expiration. Pros: Unrivaled clinical data across 30+ cancer indications. Cons: Significant "Single-Asset" risk profile. Best For: First-line immunotherapy across diverse solid tumors. Merck LogoMerck is a technology and science organization. It was found by Friedrich Jacob Merck in 1668. It is currently headquartered in Darmstadt, Germany. It includes over 250 companies along with the main company in germany Merck KGaA. Merck is a leading global biopharmaceutical company. It is one of the biggest companies that has also acted as the founding member of the oncology pharma companies’ segment.

0 · Reply

DrSammy Sep. 13 at 9:46 PM

$NVAX Supernova Vision: The Oncology Frontier: Matrix-M the T-Cells Tumor Killing Activator Machine -- Exciting (/Emotional) Times! Citi Conf Sept 10,2026

0 · Reply

TradingVolume Sep. 13 at 9:46 PM

$ICU $NVAX ~~

0 · Reply

ddirk Sep. 13 at 9:03 PM

$NVAX who is posting?

0 · Reply

TopShelfStock Sep. 13 at 7:54 PM

$NVAX Sounds like someone is holding a short position and sweating that 8-day cover ratio. 😉 Good luck out there!

0 · Reply

ddirk Sep. 13 at 7:46 PM

$NVAX so your pumping again. Do ever get tired of posting stories like yours

2 · Reply

Novavax Transcript: Citigroup’s Biopharma Back to School Summit 2026

Sep 9, 2026, 9:45 AM EDT - 4 days ago

Novavax Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 2, 2026, 5:00 PM EDT - 11 days ago

Novavax to Participate in September Investor Conferences

2026-08-28T12:35:41.000Z - 16 days ago

Novavax’s partners approved for Nuvaxovid formulation for vaccination season

SNY TAK

Aug 28, 2026, 8:30 AM EDT - 16 days ago

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

Aug 27, 2026, 5:48 PM EDT - 17 days ago

US FDA approves updated COVID vaccines for 2026-27 season

MRNA PFE SNY BNTX

Aug 6, 2026, 8:30 AM EDT - 5 weeks ago

Novavax Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 5 weeks ago

Novavax Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 5 weeks ago

Novavax Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 5 weeks ago

Novavax Slides: Q2 2026

2026-08-06T12:22:31.000Z - 5 weeks ago

Novavax reports Q2 EPS (32c), consensus (38c)

2026-08-06T12:21:31.000Z - 5 weeks ago

Novavax raises 2026 adjusted revenue view to $235M-$275M from $230M-$270M

Aug 6, 2026, 8:04 AM EDT - 5 weeks ago

Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Jul 30, 2026, 7:00 AM EDT - 6 weeks ago

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

2026-07-10T15:15:11.000Z - 2 months ago

Novavax put volume heavy and directionally bearish

Jun 24, 2026, 8:00 AM EDT - 2 months ago

Shah Capital Responds to Significant Shareholder Dissent at Novavax AGM

2026-06-22T15:15:08.000Z - 2 months ago

Novavax put volume heavy and directionally bearish

Jun 18, 2026, 8:30 AM EDT - 2 months ago

Novavax Transcript: AGM 2026

Jun 4, 2026, 10:30 AM EDT - 3 months ago

Novavax Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 4:00 PM EDT - 3 months ago

Novavax to Participate in 2026 Jefferies Global Healthcare Conference

May 13, 2026, 6:40 PM EDT - 4 months ago

Novavax Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

Novavax Slides: Corporate presentation

May 11, 2026, 7:53 AM EDT - 4 months ago

Hantavirus cases spark surge in pharma and biotech stocks — here's why

EBS INO MRNA

May 7, 2026, 4:00 PM EDT - 4 months ago

Novavax to Participate in BofA Securities 2026 Health Care Conference

May 6, 2026, 8:30 AM EDT - 4 months ago

Novavax Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

Novavax Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

Novavax Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

Novavax Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

May 6, 2026, 7:56 AM EDT - 4 months ago

Novavax beats first-quarter revenue estimates on vaccine deals strength

Apr 29, 2026, 4:00 PM EDT - 4 months ago

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Novavax Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Novavax Proxy statement: Proxy filing

Apr 8, 2026, 6:08 AM EDT - 5 months ago

Shah Capital intends to vote against Novavax's board nominees, executive compensation

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

Mar 10, 2026, 3:40 PM EDT - 6 months ago

Novavax Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 2:30 PM EST - 6 months ago

Novavax Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:30 PM EST - 6 months ago

Novavax to Participate in Upcoming Investor Conferences

Feb 26, 2026, 8:30 AM EST - 6 months ago

Novavax Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Novavax Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Novavax Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Novavax Slides: Q4 2025

Feb 26, 2026, 8:06 AM EST - 6 months ago

Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals

Feb 26, 2026, 8:00 AM EST - 6 months ago

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 19, 2026, 8:00 AM EST - 6 months ago

Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 20, 2026, 7:15 AM EST - 7 months ago

Novavax Announces Entering into a License Agreement with Pfizer

Jan 20, 2026, 7:11 AM EST - 7 months ago

Novavax enters license agreement with Pfizer for vaccine development

PFE

Jan 14, 2026, 7:30 PM EST - 8 months ago

Novavax Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:30 PM EST - 8 months ago

Novavax Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 8 months ago

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 1, 2025, 3:50 PM EST - 9 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

BNTX MRNA PFE

Dec 1, 2025, 12:35 PM EST - 9 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

BNTX MRNA PFE

Dec 1, 2025, 9:59 AM EST - 9 months ago

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

MRNA

Nov 19, 2025, 11:30 AM EST - 9 months ago

Novavax Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:41 PM EST - 10 months ago

Shah Capital pushes for Novavax sale, warns of proxy fight

Nov 12, 2025, 8:00 AM EST - 10 months ago

Novavax to Participate in Jefferies London Healthcare Conference

Nov 6, 2025, 8:30 AM EST - 10 months ago

Novavax Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Novavax Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Novavax Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Novavax Slides: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:58 AM EST - 10 months ago

Novavax raises annual revenue forecast on strength of vaccine deals

Nov 4, 2025, 7:00 AM EST - 10 months ago

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 22, 2025, 7:00 AM EDT - 10 months ago

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Oct 14, 2025, 6:09 AM EDT - 11 months ago

Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps

Oct 7, 2025, 7:00 AM EDT - 11 months ago

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Sep 30, 2025, 9:01 AM EDT - 11 months ago

Novavax Announces Progress on Sanofi Agreement

Sep 19, 2025, 11:40 AM EDT - 11 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

BNTX MRNA PFE

Sep 4, 2025, 10:20 AM EDT - 1 year ago

Novavax Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Novavax to Participate in the Cantor Global Healthcare Conference

Aug 27, 2025, 3:07 PM EDT - 1 year ago

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Aug 21, 2025, 7:43 AM EDT - 1 year ago

Novavax Announces Convertible Debt Refinancing

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Novavax Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Novavax Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Novavax Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Novavax Slides: Q2 2025

Aug 6, 2025, 8:08 AM EDT - 1 year ago

Novavax beats quarterly revenue estimates on milestone payment

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Novavax Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Novavax Slides: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 7:11 AM EDT - 1 year ago

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Jun 10, 2025, 10:45 AM EDT - 1 year ago

Vaccine actions and policy positions under US Health Secretary Kennedy

BNTX MRNA PFE

Jun 10, 2025, 9:30 AM EDT - 1 year ago

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

BNTX MRNA PFE

Jun 10, 2025, 8:18 AM EDT - 1 year ago

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

BNTX MRNA PFE SNY

May 20, 2025, 4:34 PM EDT - 1 year ago

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Trissy Sep. 14 at 2:40 AM

0 · Reply

TopShelfStock Sep. 14 at 2:13 AM

0 · Reply

ddirk Sep. 14 at 1:38 AM

1 · Reply

TopShelfStock Sep. 14 at 1:27 AM

0 · Reply

novavaxfan Sep. 13 at 10:37 PM

0 · Reply

DrSammy Sep. 13 at 9:46 PM

$NVAX Supernova Vision: The Oncology Frontier: Matrix-M the T-Cells Tumor Killing Activator Machine -- Exciting (/Emotional) Times! Citi Conf Sept 10,2026

0 · Reply

TradingVolume Sep. 13 at 9:46 PM

$ICU $NVAX ~~

0 · Reply

ddirk Sep. 13 at 9:03 PM

$NVAX who is posting?

0 · Reply

TopShelfStock Sep. 13 at 7:54 PM

$NVAX Sounds like someone is holding a short position and sweating that 8-day cover ratio. 😉 Good luck out there!

0 · Reply

ddirk Sep. 13 at 7:46 PM

$NVAX so your pumping again. Do ever get tired of posting stories like yours

2 · Reply

TopShelfStock Sep. 13 at 7:20 PM

$NVAX Or perhaps The Dream Headline below 👇 The Dream Headline: Novavax releases preclinical data proving that its Matrix-M adjuvant successfully triggers an influx of CD8+ killer T-cells directly into the tumor microenvironment. Proving that Matrix-M effectively turns "cold" tumors "hot" would make Novavax's technology an “essential component for any pharma company developing therapeutic vaccines”.

0 · Reply

TopShelfStock Sep. 13 at 7:15 PM

$NVAX The Dream Headline: The news release demonstrates that pairing a cancer antigen with Matrix-M alongside a leading checkpoint inhibitor results in significant tumor shrinkage or complete eradication in animal models. 🤔

0 · Reply

TopShelfStock Sep. 13 at 7:12 PM

$NVAX If Novavax officially proves that Matrix-M is a viable platform for oncology, it completely detaches itself from the competitive respiratory space. It would immediately be re-evaluated as an oncology platform company, similar to how the market prices biotech leaders like Moderna. Given the company's dense 30% short interest and 8.6+ days to cover, a definitive oncology licensing partnership announcement would likely be the ultimate trigger for an explosive, multi-day short squeeze 🍋🍋🍋🍋🍋

1 · Reply

TopShelfStock Sep. 13 at 6:54 PM

$NVAX Novavax (NVAX) possesses the ideal structural setup for a massive short squeeze, with a staggering 30.06% of its public float currently sold short. According to the latest data, short sellers have borrowed 48.78 million shares, resulting in a Days to Cover ratio of 8.6 days (with some exchange volumes pushing that metric past 14 days). A combination of specific, high-impact news catalysts could trigger a wave of panic buying and ignite a short squeeze

0 · Reply

TopShelfStock Sep. 13 at 6:37 PM

$NVAX Novavax's Angle: Management confirmed at the September 2026 Citi and Cantor investor conferences that they are actively testing Matrix-M in oncology, viewing cancer as the fastest path to proof-of-concept for its non-infectious disease portfolio. Any formal, positive clinical data on Matrix-M treating "cold" tumors would be a textbook "to the moon" event

0 · Reply

TopShelfStock Sep. 13 at 6:32 PM

$NVAX Near-Term $200 Million Milestone Payments from SanofiAt recent investment conferences, Novavax confirmed that Sanofi is in advanced regulatory discussions to launch a Phase 3 trial for a COVID-flu combination vaccine

0 · Reply

andy4343 Sep. 13 at 5:23 PM

$NVAX In 2021 I was indirectly told by a successful financial advisor that I have balls of steel. Good thing, because 5 years later John Jacobs keeps on kicking all of us Novavax investors in the nuts.... even the ones that don't have them! For the love of god John Jacobs, please #StopInvestorandAsianHate https://x.com/The43rdcaptain/status/2099187136473776151?s=20

0 · Reply